Eribulin

6 trials 3 recruiting LOncology

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

3 Recruiting

3 Completed trials

6 Sponsors

7 Countries

Phase III

Phase II

Phase I/II

Phase III: 1 Phase II: 4 Phase I/II: 1

Oversight events:

3 temporary halts 1 unexpected event across 2 trials

View oversight register →

Indications tested

Colorectal adenocarcinoma 1 Pleomorphic liposarcoma 1 Myxoid liposarcoma 1 HER2 positive breast cancer 1 Solitary fibrous tumour 1 Dedifferentiated liposarcoma 1 Round cell liposarcoma 1

Sponsors using this IMP

Alx Oncology Inc. 1 Delcath Systems Inc. 1 Enliven Therapeutics Inc. 1 Intensity Therapeutics Inc. 1 Italian Sarcoma Group 1 Medica Scientia Innovation Research S.L. 1

All trials

6 total

Randomized Study to Evaluate Melphalan/HDS Treatment Followed by Treatment with Eribulin or Vinorelbine or Capecitabine Versus Eribulin or V… Recruiting

2025-521966-91-00 Phase II 2 countries Delcath Systems Inc.
A study to investigate efficacy and safety of INT230-6 compared with US standard of care in participants aged ≥ 18 years old with metastatic… Recruiting

2024-512423-36-00 Phase III 5 countries Intensity Therapeutics Inc.
A Study of Evorpacept (ALX148) in Patients with Metastatic HER2-Positive Breast Cancer Recruiting

2025-522012-16-00 Phase II 3 countries Alx Oncology Holdings Inc.
ELVN-002 combined with trastuzumab +/- chemotherapy in HER2 + Solid Tumors Ended

2023-509716-29-00 Phase I/II 5 countries Enliven Therapeutics Inc.
PHASE II STUDY FOR PATIENTS WITH ADVANCED TRIPLE NEGATIVE OR METAPLASTIC HRPOSITIVE/HER2-NEGATIVE, PIK3CA/PTEN-ALTERED BREAST CANCER TREATED… Ended

2024-512963-30-00 Phase II 1 country Medica Scientia Innovation Research S.L.
ERibulin in Advanced Solitary fibrous tumor, an ItaliaN sarcoma Group phase II study (ERASING) Ended

2024-517795-38-00 Phase II 1 country Italian Sarcoma Group

Showing 1–6 of 6 trials

← All drugs A–Z